Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
نویسندگان
چکیده
منابع مشابه
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
IMPORTANCE The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of daclatasvir (a pan-genotypic NS5A inhibitor), asunaprevir (an NS3 protease inhibitor), and beclabuvi...
متن کاملDaclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
UNLABELLED All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant and 87 nonresponder patients with chronic HCV genotype 1b infection were enrol...
متن کاملDual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
BACKGROUND & AIMS Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response. METHODS In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log₁₀ HCV RNA reduction af...
متن کاملA randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
LB-7. Tarek Hassanein1,⇑ Karen D. Sims Michael Bennett Norman Gitlin Eric Lawitz Tuan Nguyen Lynn Webster Zobair Younossi Howard Schwartz Paul J. Thuluvath 11 non-financial support from AbbVie, Achillion, BioCryst, Biotica, Enanta, Gilead Sciences, Idenix, Janssen, Kadmon, Merck, Novartis, Presidio, Santaris, Theravance, and Vertex. L. Webster has received consulting fees from AcelRx, Acura, As...
متن کاملEfficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
BACKGROUND/AIMS The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection. METHODS We retrospecti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA
سال: 2015
ISSN: 0098-7484
DOI: 10.1001/jama.2015.3860